Table 1.
Clinical Features of Patients and Serum Levels of Thyroperoxidase and Myeloperoxidase
| PD (n=50) | Control (n=35) | p | |
|---|---|---|---|
| Clinical parameters | |||
| Age (years) | 63.4±2 | 67.9±10 | NS |
| Sex, male, n (%) | 24 (48) | 22 (62) | NS |
| Body–mass index | 24.2±3 | 24.3±3.5 | NS |
| Hypertension, n (%) | 20 (40) | 6 (17) | <0.001 |
| Dyslipidemia, n (%) | 11 (22) | 7 (20) | NS |
| Vitamin A/E supplement | 11 (22) | 7 (20) | NS |
| Statin use, n (%) | 6 (12) | 3 (8.5) | NS |
| Aspirin, n (%) | 8 (16) | 4 (11.4) | NS |
| Hypothyroidism (%) | 5 (10) | 2 (5.7) | NS |
| Hyperthyroidism (%) | 1 (2) | 1 (2.8) | NS |
| Peroxidases | |||
| Myeloperoxidase (ng/ml) | 41.6±6.9 | 29.2±9.5 | NS |
| Thyroperoxidase (ng/ml) | 1.1±0.5 | 0.36±0.1 | NS |
| TPO early PD (ng/ml) | 2.1±0.6a | ||
| TPO advanced PD (ng/ml) | 0.4±0.4 | ||
Mean±SEM. Statistical comparisons were carried out with the χ2 test (qualitative variables) or Student's t-test (quantitative variables).
a
p<0.01 versus TPO levels of advanced PD patients and controls.
PD, Parkinson's disease; TPO, thyroperoxidase.